VMT Scientific Inc. Announces Confirmation Of Alignment With Key Research Laboratory And Clinical Researcher

LAS VEGAS, Nov. 9 /PRNewswire-FirstCall/ -- VMT Scientific, Inc. , after extensive meetings and discussions with top medical researcher M. Arthur Charles MD, PhD, Director of the University Clinical Investigators Inc. located in Tustin, CA., have agreed to provide the laboratory and research services needed for the clinical trials. This agreement places VMT Scientific, Inc. firmly on track to begin Clinical Trials soon. We are pleased that globally recognized Jacques D. Barth, MD, PhD, FACC, FAHA and M. Arthur Charles MD, PhD both were able to conclude proper due-diligence and evaluate the potential of the VasCir(TM) device and agreed to be part of this history making technology. A preliminary meeting is set for later this week between Brian Mc Glynn our VP of Medical Research and Jacques D. Barth, MD, PhD, FACC, FAHA our Principle Investigator to begin working out the clinical protocols needed. Understanding the emotional value and medical benefits our product brings to all Diabetics suffering from PVD. "We are all about saving Limbs says VMT Scientific." Visit our web site at http://www.vmtf.com.

This Press Release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward- looking statements, particularly those risks and uncertainties inherent in the process of developing, medical products and Clinical trials. Factors that may cause such a difference include risks related to VMT Scientific Inc.'s limited operating history, risks associated with completing development and obtaining FDA medical approvals, successful patent protection and prosecution, successful sale of licensed technology nationally or internationally. VMT Scientific technology will not meet with market acceptance, the risk of future warranty and product liability claims, the uncertainty of VMT Scientifics' future access to capital to sustain operations, achieve profitability or continue as a going concern, the failure by VMT Scientific to secure and maintain relationships with suppliers, manufacturers and other third parties, reliance on key employees, and dependence on intellectual property. These forward-looking statements are based on information and management's expectations as of the date hereof. Future results may differ materially from our current expectations.

CONTACT: Catherine S. Ratelle, Director of Operations, VMT Scientific,Inc., +1-702-990-3477, docs@vmtf.com

Web site: http://www.vmtf.com/